These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22004109)

  • 21. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells.
    Zhang L; Pang E; Loo RR; Rao J; Go VL; Loo JA; Lu QY
    Proteomics; 2011 Dec; 11(24):4638-47. PubMed ID: 22116673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
    Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
    Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
    Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.
    Suenaga S; Kuramitsu Y; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K
    Anticancer Res; 2014 Jan; 34(1):141-6. PubMed ID: 24403454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased HSP27 correlates with malignant biological behavior of non-small cell lung cancer and predicts patient's survival.
    Sheng B; Qi C; Liu B; Lin Y; Fu T; Zeng Q
    Sci Rep; 2017 Oct; 7(1):13807. PubMed ID: 29062135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
    Delgado-Coka LA; Roa-Peña L; Babu S; Horowitz M; Petricoin EF; Matrisian LM; Blais EM; Marchenko N; Allard FD; Akalin A; Jiang W; Larson BK; Hendifar AE; Picozzi VJ; Choi M; Shroyer KR; Escobar-Hoyos LF
    Am J Clin Pathol; 2024 Sep; 162(3):314-326. PubMed ID: 38642081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27.
    Fanelli MA; Montt-Guevara M; Diblasi AM; Gago FE; Tello O; Cuello-Carrión FD; Callegari E; Bausero MA; Ciocca DR
    Cell Stress Chaperones; 2008; 13(2):207-20. PubMed ID: 18320359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
    Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
    Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.
    Zhao Y; Altendorf-Hofmann A; Pozios I; Camaj P; Däberitz T; Wang X; Niess H; Seeliger H; Popp F; Betzler C; Settmacher U; Jauch KW; Bruns C; Knösel T
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1061-1068. PubMed ID: 28210844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines.
    Forika G; Kiss E; Petovari G; Danko T; Gellert AB; Krenacs T
    Pathol Oncol Res; 2021; 27():1610048. PubMed ID: 34955688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma.
    Wang W; Xu X; Wang W; Shao W; Li L; Yin W; Xiu L; Mo M; Zhao J; He Q; He J
    Tumour Biol; 2011 Dec; 32(6):1199-208. PubMed ID: 21858536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
    Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
    BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
    Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A
    J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.
    Bauer K; Nitsche U; Slotta-Huspenina J; Drecoll E; von Weyhern CH; Rosenberg R; Höfler H; Langer R
    Cell Oncol (Dordr); 2012 Jun; 35(3):197-205. PubMed ID: 22535481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
    Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
    Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
    World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.